文献速递肿瘤 PET/CT

18F-FDG PET/CT在胃癌腹膜转移患者转化手术后术前评估与预后预测中的价值

Preoperative assessment and prognostic prediction of gastric cancer patients with peritoneal metastasis using 18F-FDG PET/CT before conversion surgery.
PubMed 文献 · EJNMMI Res · 2025-04-21

这项回顾性研究纳入51例胃癌腹膜转移患者,评估转化治疗后18F-FDG PET/CT在术前评估和预后预测中的价值。PET/CT对残余腹膜病灶的诊断准确率略优于增强CT(72.5% vs 61.2%,P=0.229),差异无统计学意义。腹膜病灶TBR是术前评估的最佳预测指标(TBRAmaxp截断值0.705,特异度80%,灵敏度80%,AUC 0.825,P<0.001),SUVmaxp是24个月生存的最佳预测指标(截断值1.466,AUC 0.870,P=0.002)。

要点

  • PET/CT对残余腹膜病灶诊断准确率72.5%,增强CT为61.2%,差异无统计学意义(P=0.229)。
  • TBRAmaxp截断值0.705预测腹膜病灶,特异度80%、灵敏度80%、AUC 0.825(P<0.001)。
  • SUVmaxp截断值1.466预测24个月生存,AUC 0.870(P=0.002),特异度77.8%、灵敏度83.3%。

核心结论

  • 18F-FDG PET/CT可为胃癌腹膜转移患者的术前评估和预后预测提供定量影像指标。
  • 腹膜病灶代谢参数可预测总生存及接受转化手术患者的预后。

研究设计与样本

  • 回顾性研究,纳入51例胃癌腹膜转移患者,评估转化治疗后18F-FDG PET/CT的术前评估与预后预测价值。

主要发现

  • PET/CT对残余腹膜病灶的诊断准确率为72.5%,增强CT为61.2%,差异无统计学意义(P=0.229)。
  • 腹膜病灶TBR有助于术前评估,TBRAmaxp为最佳预测指标(截断值0.705,特异度80%,灵敏度80%,AUC 0.825,P<0.001)。
  • SUVmaxp为24个月生存的最佳预测指标(截断值1.466,AUC 0.870,P=0.002,特异度77.8%,灵敏度83.3%)。
  • 腹膜病灶代谢参数可预测总生存及接受转化手术患者的预后。

关键数值与推荐

  • 残余腹膜病灶诊断准确率:PET/CT 72.5% vs 增强CT 61.2%(P=0.229,差异无统计学意义)。
  • TBRAmaxp预测腹膜病灶:截断值0.705,特异度80%,灵敏度80%,AUC 0.825,P<0.001。
  • SUVmaxp预测24个月生存:截断值1.466,AUC 0.870,P=0.002,特异度77.8%,灵敏度83.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conversion therapy followed by conversion surgery (CS) can improve the prognosis of gastric cancer (GC) patients with peritoneal metastasis (PM). However, patients benefit differently. There is no way to confirm the prognostic benefit non-invasively and early. This retrospective study assessed the value of 18F-FDG PET/CT after conversion therapy in preoperative assessment and prognostic prediction of GC patients with PM. RESULTS: Fifty-one GC patients with PM were enrolled. 18F-FDG PET/CT after conversion therapy helped in preoperative assessment. Its diagnostic accuracy for residual peritoneal lesions was slightly better than contrast-enhanced CT (72.5% vs. 61.2%, P = 0.229), although the difference was not statistically significant. TBR of peritoneal lesions could help preoperative assessment, with TBR of peritoneal lesions to the mediastinal blood pool SUVmax (TBRAmaxp) as the best predictor (cutoff = 0.705, specificity 80%, sensitivity 80%, AUC 0.825, P < 0.001). Additionally, PET/CT could predict prognosis and assess surgical benefit. SUVmax of peritoneal lesions (SUVmaxp) was the best predictor of 24 months survival (cutoff = 1.466, AUC 0.870, P = 0.002, Specificity 77.8%, Sensitivity 83.3%) and metabolic parameters of peritoneal lesions could predict OS and the prognosis of patients who underwent CS. CONCLUSION: 18F-FDG PET/CT provides quantitative imaging indicators for preoperative evaluation and prognostic prediction in GC patients with PM.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Peng Y, Shi M, Xiong D, et al. Preoperative assessment and prognostic prediction of gastric cancer patients with peritoneal metastasis using 18F-FDG PET/CT before conversion surgery. EJNMMI Res. 2025. PMID: 40257553. doi:10.1186/s13550-025-01244-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。